Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review

Clinical Biochemistry

Volumn 44, Issue 1, 2011, Pages 119-135

  Roux, Aurélie ^a   Lison, Dominique ^b   Junot, Christophe ^a   Heilier, Jean François ^a,b,c  

^a Institut National de la Recherche Agronomique   (France)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c INSTITUT NATIONAL DE RECHERCHE ET DE SÉCURITÉ   (France)

Author keywords

Biomarkers; LC MS; Metabolomics; Metabonomics; Toxicology

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DISOPYRAMIDE; ENTACAPONE; GENTAMICIN; GLYCERIC ACID; ION; LIPID; PARACETAMOL; RIMONABANT; ROFECOXIB; SEBACIC ACID; SUGAR; TOBRAMYCIN; TOLCAPONE; XANTHURENIC ACID; XENOBIOTIC AGENT;

ALCOHOLISM; BIOLOGICAL MONITORING; CANCER DIAGNOSIS; CLINICAL CHEMISTRY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL DETECTION; TOXICOLOGY;

CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; METABOLOMICS; TOXICOLOGY;

EID: 78650907092     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.016     Document Type: Review

References (168)

1. Herbert R.B. The biosynthesis of secondary metabolites 1989, Chapman and Hall. 2nd ed.
2. Shargel L., Yu A. Applied biopharmaceutics and pharmacokinetics 1999, McGraw-Hill. 4th ed.
3. Holmes E., Loo R.L., Cloarec O., et al. Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal Chem 2007, 79:2629-2640.
4. Wishart D.S. Metabolomics: applications to food science and nutrition research. Trends Food Sci Technol 2008, 19:482-493.
5. DeCaprio A.P. Biomarkers: coming of age for environmental health and risk assessment. Environ Sci Technol 1997, 31:1837-1848.
6. Wolfe D.A. Insights on the utility of biomarkers for environmental impact assessment and monitoring. Hum Ecol Risk Assess 1996, 2:245-250.
7. Crockford D.J., Maher A.D., Ahmadi K.R., et al. 1H NMR and UPLC-MS(E) statistical heterospectroscopy: characterization of drug metabolites (xenometabolome) in epidemiological studies. Anal Chem 2008, 80:6835-6844.
8. Gates S.C., Sweeley C.C. Quantitative metabolic profiling based on gas chromatography. Clin Chem 1978, 24:1663-1673.
9. [9] Williams RJ. Individual metabolic patterns and human disease: an exploratory study utilizing predominantly paper chromatographic methods. Austin: Univ. Texas, 1951.
10. Williams R.J. Biochemical individuality 1956, John Wiley & Sons.
11. Griffiths W.J., Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev 2009, 38:1882-1896.
12. Horning E.C., Horning M.G. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin Chem 1971, 17:802-809.
13. Horning E.C., Horning M.G. Human metabolic profiles obtained by GC [gas chromatography] and GC/MS [gas chromatography/mass spectrometry]. J Chromatogr Sci 1971, 9:129-140.
14. Pauling L., Robinson A.B., Teranishi R., Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci USA 1971, 68:2374-2376.
15. Oliver S.G., Winson M.K., Kell D.B., Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol 1998, 16:373-378.
16. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002, 48:155-171.
17. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010, 243:154-166.
18. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
19. Lindon J.C., Nicholson J.K., Holmes E., et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol 2003, 187:137-146.
20. Bennett D.A., Waters M.D. Applying biomarker research. Environ Health Perspect 2000, 108:907-910.
21. Paustenbach D.J. The practice of exposure assessment. Principles and methods of toxicology 2001, Taylor and Francis, London. A.W. Hayes (Ed.).
22. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
23. Timbrell J.A. Biomarkers in toxicology. Toxicology 1998, 129:1-12.
24. Kehoe R.A., Thamann F., Cholak J. Lead absorption and excretion in relation to the diagnosis of lead poisoning. J Ind Hyg Toxicol 1933, 15:320-340.
25. Pearce S.J., Schrenk H.H., Yant W.P. Microcolorimetric determination of benzene in blood and urine 1936.
26. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: state of the art. Int J Hyg Environ Health 2007, 210:201-228.
27. Haufroid V., Jakubowski M., Janasik B., et al. Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene. Pharmacogenetics 2002, 12:691-702.
28. Clayton T.A., Lindon J.C., Cloarec O., et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440:1073-1077.
29. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009, 106:14728-14733.
30. Holmes E., Nicholls A.W., Lindon J.C., et al. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 1998, 11:235-244.
31. Aharoni A., Ric D.V., Verhoeven H.A., et al. Nontargeted metabolome analysis by use of Fourier transform ion cyclotron mass spectrometry. OMICS 2002, 6:217-234.
32. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007, 26:51-78.
33. Fiehn O., Kopka J., Trethewey R.N., Willmitzer L. Identification of uncommon plant metabolites based on calculation of elemental compositions using gas chromatography and quadrupole mass spectrometry. Anal Chem 2000, 72:3573-3580.
34. Huang G., Chen H., Zhang X., Cooks R.G., Ouyang Z. Rapid screening of anabolic steroids in urine by reactive Desorption electrospray ionization. Anal Chem 2007, 79:8327-8332.
35. Jia L.W., Wang C., Zhao S.M., Lu X., Xu G.W. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2007, 860:134-140.
36. Trauger S.A., Go E.P., Shen Z., et al. High sensitivity and analyte capture with desorption/ionization mass spectrometry on silylated porous silicon. Anal Chem 2004, 76:4484-4489.
37. Vaidyanathan S., Gaskell S., Goodacre R. Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid Commun Mass Spectrom 2006, 20:1192-1198.
38. Vaidyanathan S., Jones D., Ellis J., et al. Laser desorption/ionization mass spectrometry on porous silicon for metabolome analyses: influence of surface oxidation. Rapid Commun Mass Spectrom 2007, 21:2157-2166.
39. Wilson I.D., Nicholson J.K., Castro-Perez J., et al. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res 2005, 4:591-598.
40. Vaidyanathan S., Jones D., Jenkins T., Kell D.B., Goodacre R. Metabolomic investigations using laser desorption ionisation mass spectrometry on porous silicon. Abstracts of papers of the American Chemical Society 2005, 229:U245.
41. Lindon J.C., Nicholson J.K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem 2008, 1:45-69.
42. Lenz E.M., Bright J., Wilson I.D., Morgan S.R., Nash A.F. A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 2003, 33:1103-1115.
43. Nicholson J.K., Higham D.P., Timbrell J.A., Sadler P.J. Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat. Mol Pharmacol 1989, 36:398-404.
44. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1:153-161.
45. Park S.Y., Kim Y.W., Kim J.E., Kim J.Y. Age-associated changes in fat metabolism in the rat and its relation to sympathetic activity. Life Sci 2006, 79:2228-2233.
46. Hodson M.P., Dear G.J., Roberts A.D., et al. A gender-specific discriminator in Sprague-Dawley rat urine: the deployment of a metabolic profiling strategy for biomarker discovery and identification. Anal Biochem 2007, 362:182-192.
47. Plumb R., Granger J., Stumpf C., et al. Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. Analyst 2003, 128:819-823.
48. Williams R.E., Lenz E.M., Evans J.A., et al. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J Pharm Biomed Anal 2005, 38:465-471.
49. Ebbels T.M., Holmes E., Lindon J.C., Nicholson J.K. Evaluation of metabolic variation in normal rat strains from a statistical analysis of 1H NMR spectra of urine. J Pharm Biomed Anal 2004, 36:823-833.
50. Gavaghan C.L., Holmes E., Lenz E., Wilson I.D., Nicholson J.K. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 2000, 484:169-174.
51. Gu H., Chen H., Pan Z., et al. Monitoring diet effects via biofluids and their implications for metabolomics studies. Anal Chem 2007, 79:89-97.
52. Phipps A.N., Stewart J., Wright B., Wilson I.D. Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 1998, 28:527-537.
53. Wikoff W.R., Anfora A.T., Liu J., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009, 106:3698-3703.
54. Lawton K.A., Berger A., Mitchell M., et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 2008, 9:383-397.
55. Saude E.J., Adamko D., Rowe B.H., Marrie T., Sykes B.D. Variation of metabolites in normal human urine. Metabolomics 2007, 3:439-451.
56. Warrack B.M., Hnatyshyn S., Ott K.H., et al. Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B Anal Technol Biomed Life Sci 2009, 877:547-552.
57. Jankevics A., Liepinsh E., Liepinsh E., et al. Metabolomic studies of experimental diabetic urine samples by H-1 NMR spectroscopy and LC/MS method. Chemom Intell Lab Syst 2009, 97:11-17.
58. Wang J., Reijmers T., Chen L., et al. Systems toxicology study of doxorubicin on rats using ultra performance liquid chromatography coupled with mass spectrometry based metabolomics. Metabolomics 2009, 5:407-418.
59. Werner E., Croixmarie V., Umbdenstock T., et al. Mass spectrometry-based metabolomics: accelerating the characterization of discriminating signals by combining statistical correlations and ultrahigh resolution. Anal Chem 2008, 80:4918-4932.
60. Bruce S.J., Tavazzi I., Parisod V., et al. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Anal Chem 2009, 81:3285-3296.
61. Want E.J., O'Maille G., Smith C.A., et al. Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 2006, 78:743-752.
62. Croixmarie V., Umbdenstock T., Cloarec O., et al. Integrated comparison of drug-related and drug-induced ultra performance liquid chromatography/mass spectrometry metabonomic profiles using human hepatocyte cultures. Anal Chem 2009, 81:6061-6069.
63. Soga T., Baran R., Suematsu M., et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006, 281:16768-16776.
64. Soga T., Igarashi K., Ito C., et al. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal Chem 2009, 81:6165-6174.
65. Idborg-Bjorkman H., Edlund P.O., Kvalheim O.M., Schuppe-Koistinen I., Jacobsson S.P. Screening of biomarkers in rat urine using LC/electrospray ionization-MS and two-way data analysis. Anal Chem 2003, 75:4784-4792.
66. Plumb R.S., Stumpf C.L., Gorenstein M.V., et al. Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. Rapid Commun Mass Spectrom 2002, 16:1991-1996.
67. Lafaye A., Junot C., Ramounet-Le G.B., et al. Metabolite profiling in rat urine by liquid chromatography/electrospray ion trap mass spectrometry. Application to the study of heavy metal toxicity. Rapid Commun Mass Spectrom 2003, 17:2541-2549.
68. Madalinski G., Godat E., Alves S., et al. Direct introduction of biological samples into a LTQ-Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. Anal Chem 2008, 80:3291-3303.
69. Hodson M.P., Dear G.J., Griffin J.L., Haselden J.N. An approach for the development and selection of chromatographic methods for high-throughput metabolomic screening of urine by ultra pressure LC-ESI-ToF-MS. Metabolomics 2009, 5:166-182.
70. Guy P.A., Tavazzi I., Bruce S.J., Ramadan Z., Kochhar S. Global metabolic profiling analysis on human urine by UPLC-TOFMS: issues and method validation in nutritional metabolomics. J Chromatogr B Anal Technol Biomed Life Sci 2008, 871:253-260.
71. Redestig H., Fukushima A., Stenlund H., et al. Compensation for systematic cross-contribution improves normalization of mass spectrometry based metabolomics data. Anal Chem 2009, 81:7974-7980.
72. Draisma H.H.M., Reijmers T.H., van der Kloet F., et al. Equating, or correction for between-block effects with application to body fluid LC-MS and NMR metabolomics data sets. Anal Chem 2010, 82:1039-1046.
73. Wagner S., Scholz K., Sieber M., Kellert M., Voelkel W. Tools in metabonomics: an integrated validation approach for LC-MS metabolic profiling of mercapturic acids in human urine. Anal Chem 2007, 79:2918-2926.
74. Rew R.K., Davis G.P. NetCDF: an interface for scientific data access. IEEE Comput Graph Appl 1990, 10:76-82.
75. Pedrioli P.G., Eng J.K., Hubley R., et al. A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol 2004, 22:1459-1466.
76. Katajamaa M., Oresic M. Data processing for mass spectrometry-based metabolomics. J Chromatogr A 2007, 1158:318-328.
77. Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 2006, 78:779-787.
78. Tautenhahn R., Bottcher C., Neumann S. Highly sensitive feature detection for high resolution LC/MS. BMC Bioinform 2008, 9:504.
79. Katajamaa M., Miettinen J., Oresic M. MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 2006, 22:634-636.
80. Baran R., Kochi H., Saito N., et al. MathDAMP: a package for differential analysis of metabolite profiles. BMC Bioinform 2006, 7:530.
81. Wiklund S., Johansson E., Sjostrom L., et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008, 80:115-122.
82. Trygg J., Holmes E., Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007, 6:469-479.
83. Madsen R., Lundstedt T., Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal Chim Acta 2010, 659:23-33.
84. Matsuda F., Yonekura-Sakakibara K., Niida R., et al. MS/MS spectral tag-based annotation of non-targeted profile of plant secondary metabolites. Plant J 2009, 57:555-577.
85. Werner E., Heilier J.F., Ducruix C., et al. Mass spectrometry for the identification of the discriminating signals from metabolomics: current status and future trends. J Chromatogr B Anal Technol Biomed Life Sci 2008, 871:143-163.
86. Sumner L.W., Urbanczyk-Wochniak E., Broeckling C.D. Metabolomics data analysis, visualization, and integration. Methods Mol Biol 2007, 406:409-436.
87. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004, 351:1707-1709.
88. Wathion N. Public statement on Acomplia (rimonabant). Withdrawal of the marketing authorisation in the European Union 2009, European Medicines Agency.
89. Gant T.W. Novel and future applications of microarrays in toxicological research. Expert Opin Drug Metab Toxicol 2007, 3:599-608.
90. Merrick B.A., Tomer K.B. Toxicoproteomics: a parallel approach to identifying biomarkers. Environ Health Perspect 2003, 111:A578-A579.
91. Griffin J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 2003, 7:648-654.
92. Keun H.C. Metabonomic modeling of drug toxicity. Pharmacol Ther 2006, 109:92-106.
93. Lindon J.C., Holmes E., Bollard M.E., Stanley E.G., Nicholson J.K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9:1-31.
94. Robertson D.G. Metabonomics in toxicology: a review. Toxicol Sci 2005, 85:809-822.
95. Robertson D.G., Reily M.D., Baker J.D. Metabonomics in preclinical drug development. Expert Opin Drug Metab Toxicol 2005, 1:363-376.
96. Shockcor J.P., Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2002, 2:35-51.
97. Timbrell J.A. Principles of biochemical toxicology. Informa Healthcare 1999, 3rd Revised edition.
98. Sun J., Schnackenberg L.K., Holland R.D., et al. Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J Chromatogr B Anal Technol Biomed Life Sci 2008, 871:328-340.
99. Schnackenberg L.K., Chen M., Sun J., et al. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol Appl Pharmacol 2009, 235:25-32.
100. Sun J., Schnackenberg L.K., Beger R.D. Studies of acetaminophen and metabolites in urine and their correlations with toxicity using metabolomics. Drug Metab Lett 2009, 3:130-136.
101. Chen C., Krausz K.W., Shah Y.M., Idle J.R., Gonzalez F.J. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2009, 22:699-707.
102. La S., Yoo H.H., Kim D.H. Liquid chromatography-mass spectrometric analysis of urinary metabolites and their pattern recognition for the prediction of drug-induced hepatotoxicity. Chem Res Toxicol 2005, 18:1887-1896.
103. Boudonck K.J., Mitchell M.W., Nemet L., et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 2009, 37:280-292.
104. van Vliet E., Morath S., Eskes C., et al. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 2008, 29:1-12.
105. Ganote C.E., Peterson D.R., Carone F.A. The nature of d-serine-induced nephrotoxicity. Am J Pathol 1974, 77:269-282.
106. Williams R.E., Jacobsen M., Lock E.A. 1H NMR pattern recognition and 31P NMR studies with d-Serine in rat urine and kidney, time- and dose-related metabolic effects. Chem Res Toxicol 2003, 16:1207-1216.
107. Williams R.E., Major H., Lock E.A., Lenz E.M., Wilson I.D. d-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology 2005, 207:179-190.
108. Ringeissen S., Connor S.C., Brown H.R., et al. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers 2003, 8:240-271.
109. Williams R.E., Lock E.A. Sodium benzoate attenuates d-serine induced nephrotoxicity in the rat. Toxicology 2005, 207:35-48.
110. McBurney R.N., Hines W.M., Von Tungeln L.S., et al. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol Pathol 2009, 37:52-64.
111. Chace D.H. Mass spectrometry in the clinical laboratory. Chem Rev 2001, 101:445-477.
112. Folch J., Ascoli I., Lees M., Meath J.A., Lebaron N. Preparation of lipide extracts from brain tissue. J Biol Chem 1951, 191:833-841.
113. Sabatine M.S., Liu E., Morrow D.A., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
114. Lewis G.D., Wei R., Liu E., et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008, 118:3503-3512.
115. Turer A.T., Stevens R.D., Bain J.R., et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 2009, 119:1736-1746.
116. Shaham O., Slate N.G., Goldberger O., et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci USA 2010, 107:1571-1575.
117. Oresic M., Simell S., Sysi-Aho M., et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008, 205:2975-2984.
118. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
119. Ritchie S.A., Ahiahonu P.W., Jayasinghe D., et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010, 8:13.
120. Wishart D.S. Human Metabolome Database: completing the 'human parts list'. Pharmacogenomics 2007, 8:683-686.
121. Kanehisa M., Araki M., Goto S., et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008, 36:D480-D484.
122. Smith C.A., O'Maille G., Want E.J., et al. METLIN: a metabolite mass spectral database. Ther Drug Monit 2005, 27:747-751.
123. Bogusz M.J., Maier R.D., Kruger K.D., et al. Poor reproducibility of in-source collisional atmospheric pressure ionization mass spectra of toxicologically relevant drugs. J Chromatogr A 1999, 844:409-418.
124. Cui Q., Lewis I.A., Hegeman A.D., et al. Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol 2008, 26:162-164.
125. Palit M., Mallard G. Fragmentation energy index for universalization of fragmentation energy in ion trap mass spectrometers for the analysis of chemical weapon convention related chemicals by atmospheric pressure ionization-tandem mass spectrometry analysis. Anal Chem 2009, 81:2477-2485.
126. Oberacher H., Pavlic M., Libiseller K., et al. On the inter-instrument and inter-laboratory transferability of a tandem mass spectral reference library: 1. Results of an Austrian multicenter study. J Mass Spectrom 2009, 44:485-493.
127. Oberacher H., Pavlic M., Libiseller K., et al. On the inter-instrument and the inter-laboratory transferability of a tandem mass spectral reference library: 2. Optimization and characterization of the search algorithm. J Mass Spectrom 2009, 44:494-502.
128. Chan W., Cai Z. Aristolochic acid induced changes in the metabolic profile of rat urine. J Pharm Biomed Anal 2008, 46:757-762.
129. Chan W., Lee K.C., Liu N., et al. Liquid chromatography/mass spectrometry for metabonomics investigation of the biochemical effects induced by aristolochic acid in rats: the use of information-dependent acquisition for biomarker identification. Rapid Commun Mass Spectrom 2008, 22:873-880.
130. Lin Y., Si D., Zhang Z., Liu C. An integrated metabonomic method for profiling of metabolic changes in carbon tetrachloride induced rat urine. Toxicology 2009, 256:191-200.
131. Ohta T., Masutomi N., Tsutsui N., et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 2009, 37:521-535.
132. Sieber M., Wagner S., Rached E., et al. Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem Res Toxicol 2009, 22:1221-1231.
133. Lenz E.M., Bright J., Knight R., Wilson I.D., Major H. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004, 129:535-541.
134. Sun J., Von Tungeln L.S., Hines W., Beger R.D. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. J Chromatogr B Anal Technol Biomed Life Sci 2009, 877:2557-2565.
135. Wagner S., Scholz K., Donegan M., et al. Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Anal Chem 2006, 78:1296-1305.
136. Lenz E.M., Bright J., Knight R., Wilson I.D., Major H. Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004, 35:599-608.
137. Patterson A.D., Li H., Eichler G.S., et al. UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 2008, 80:665-674.
138. Yang L., Xiong A., He Y., et al. Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem Res Toxicol 2008, 21:2280-2288.
139. Kind T., Tolstikov V., Fiehn O., Weiss R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007, 363:185-195.
140. Kim K., Aronov P., Zakharkin S.O., et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009, 8:558-570.
141. Woo H.M., Kim K.M., Choi M.H., et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009, 400:63-69.
142. Cho S.H., Choi M.H., Lee W.Y., Chung B.C. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clin Biochem 2009, 42:540-543.
143. Cho S.H., Jung B.H., Lee S.H., et al. Direct determination of nucleosides in the urine of patients with breast cancer using column-switching liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2006, 20:1229-1236.
144. Frickenschmidt A., Frohlich H., Bullinger D., et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008, 13:435-449.
145. Guan W., Zhou M., Hampton C.Y., et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 2009, 10:259.
146. Issaq H.J., Nativ O., Waybright T., et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008, 179:2422-2426.
147. Ma Y.L., Qin H.L., Liu W.J., et al. Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig Dis Sci 2009, 54(N12):2655-2662.
148. Yan S.K., Wei B.J., Lin Z.Y., et al. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol 2008, 44:477-483.
149. Osl M., Dreiseitl S., Pfeifer B., et al. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 2008, 24:2908-2914.
150. Wang Z., Tang W.H., Cho L., Brennan D.M., Hazen S.L. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009, 29:1383-1391.
151. Lin H., Zhang J., Gao P. Silent myocardial ischemia is associated with altered plasma phospholipids. J Clin Lab Anal 2009, 23:45-50.
152. Wang C., Kong H., Guan Y., et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005, 77:4108-4116.
153. Yang J., Zhao X., Liu X., et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J Proteome Res 2006, 5:554-561.
154. Mutch D.M., Fuhrmann J.C., Rein D., et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 2009, 4:e7905.
155. van Ginneken V., Verhey E., Poelmann R., et al. Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis. Biochim Biophys Acta 2007, 1771:1263-1270.
156. Yin P., Zhao X., Li Q., et al. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J Proteome Res 2006, 5:2135-2143.
157. Jansson J., Willing B., Lucio M., et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS ONE 2009, 4:e6386.
158. Duarte I.F., Legido-Quigley C., Parker D.A., et al. Identification of metabolites in human hepatic bile using 800MHz 1H NMR spectroscopy, HPLC-NMR/MS and UPLC-MS. Mol Biosyst 2009, 5:180-190.
159. Li Q., Zhang Q., Xu G., et al. Metabonomics study of intestinal transplantation using ultrahigh-performance liquid chromatography time-of-flight mass spectrometry. Digestion 2008, 77:122-130.
160. Greenberg N., Grassano A., Thambisetty M., Lovestone S., Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 2009, 30:1235-1239.
161. Rozen S., Cudkowicz M.E., Bogdanov M., et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005, 1:101-108.
162. Marhuenda-Egea F.C., Martinez-Sabater E., Gonsalvez-Alvarez R., et al. A crucial step in assisted reproduction technology: human embryo selection using metabolomic evaluation. Fertil Steril 2009.
163. Shah DK, Doyle LW, Anderson PJ, et al. Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. J Pediatr 2008;153: 170-5, 175.
164. Yin P., Mohemaiti P., Chen J., et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2008, 871:322-327.
165. Lankinen M., Schwab U., Gopalacharyulu P.V., et al. Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2010, 20(N4):249-257.
166. Gao P., Lu C., Zhang F., et al. Integrated GC-MS and LC-MS plasma metabonomics analysis of ankylosing spondylitis. Analyst 2008, 133:1214-1220.
167. Beger R.D., Holland R.D., Sun J., et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr Nephrol 2008, 23:977-984.
168. Wikoff W.R., Gangoiti J.A., Barshop B.A., Siuzdak G. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin Chem 2007, 53:2169-2176.